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To determine frequency of methicillin-resistant
Staphylococcus aureus infections caused by strains typi-
cally associated with community-acquired infections
(USA300) among persons with healthcare-related risk fac-
tors (HRFs), we evaluated surveillance data. Of patients
with HRFs, 18%–28% had a “community-associated”
strain, primarily USA300; of patients without HRFs, 26%
had a “healthcare-associated” strain, typically USA100.
I
n the United States, initial reports of methicillin-resistant
Staphylococcus aureus (MRSA) infections among injec-
tion drug users in Detroit in 1981 were followed by reports
of MRSA associated with the deaths of 4 children in
Minnesota and North Dakota in 1997 (1). For the next few
years, public health personnel in several states investigat-
ed outbreaks of MRSA infections of skin and soft tissue
among diverse populations who typically had little or no
previous contact with the healthcare system, such as
Native Americans (2), sports teams (3), prison inmates (4),
and child-care facility attendees (5). These outbreaks were
initially associated with a novel MRSA strain known as
MW2, or pulsed-field gel electrophoresis (PFGE) type
USA400, but were soon replaced by a strain of MRSA
belonging to PFGE type USA300 (6). Through 2002, the
clinical appearance of cases and the microbiologic charac-
teristics of USA300 and USA400 differed substantially
from those associated with strains of MRSA acquired in
healthcare settings (7). Increasingly, MRSA strains of
community origin are causing healthcare-associated dis-
ease (8,9). We evaluated surveillance data from a multisite
project to determine the frequency with which infections
among patients with healthcare-related risk factors (HRFs)
were caused by USA300 or other strains of community ori-
gin.
The Study
Active, population-based surveillance for invasive
MRSA infections is ongoing in 9 US states (California,
Colorado, Connecticut, Georgia, Maryland, Minnesota,
New York, Oregon, and Tennessee) through the Active
Bacterial Core Surveillance system in the Emerging
Infections Program at the Centers for Disease Control and
Prevention (CDC). Personnel in each state actively collect
laboratory reports of positive MRSA cultures from nor-
mally sterile sites (e.g., blood; cerebrospinal, joint, or pleu-
ral fluid) of residents in their catchment areas to identify
cases. In 2005, the estimated combined population under
surveillance was 16.3 million, according to data from the
US Bureau of the Census. To report a case, personnel must
link a laboratory report to the patient’s medical record.
During record reviews, personnel abstract information
about the following HRFs: culture obtained >48 hours
after admission; presence of an invasive device (e.g., vas-
cular catheter, G-tube); and history of MRSA infection or
colonization, surgery, hospitalization, dialysis, or resi-
dence in a long-term care facility in the 12 months preced-
ing the culture. Case-patients may have >1 HRF. For this
analysis, we used information from the record review to
classify cases into 3 mutually exclusive groups: 1) case-
patients with classic healthcare-associated infections (HA)
whose culture was obtained >48 hours after admission
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but with community onset (i.e., whose cultures were
obtained <48 hours after admission) (HACO); and 3) case-
patients with community-associated (CA) infections with-
out HRFs, according to medical record review.
A subset of isolates from case-patients was collected
from laboratories that voluntarily submitted them for
microbiologic characterization. Of the isolates received at
CDC by October 2005, a sample of 100 was selected for
testing as follows. First, isolates were stratified by
Emerging Infections Program site; none were available
from Maryland. Second, all isolates from tissues other than
blood were selected from each Emerging Infections
Program site. To ensure 12–13 isolates per site, we select-
ed blood isolates from case-patients classified as CA and
obtained the remainder from samples from HAand HACO
case-patients. Isolates were tested by PFGE; patterns were
analyzed by using BioNumerics (Applied Maths, Austin,
TX, USA). Isolates were grouped into PFGE types using
Dice coefficients and 80% relatedness (10). We considered
isolates with PFGE types USA300, 400, or 1000 to be of
community origin and those with types USA100, 200, and
500 to be of healthcare origin as previously described (10).
Statistical analysis consisted of comparisons of propor-
tions between CA and HA and between CA and HACO
cases using χ2 pairwise comparisons. Differences in medi-
an age were tested by using Wilcoxon rank sum test.
Of 9,147 cases of invasive MRSA infection investigat-
ed from January 2004 through February 2006, 2,535 (28%)
were HA, 5,353 (59%) were HACO, and 1,259 (14%)
were CA. The median age of case-patients with HA and
HACO was significantly higher than that of case-patients
with CA(Table 1). CAcase-patients were 1) more likely to
have pneumonia than HACO but not HA case-patients; 2)
more likely to have endocarditis than either HA or HACO
case-patients; and 3) less likely to die during this hospital
stay than were HA or HACO case-patients.
Of the 100 isolates selected for initial testing, 29 were
from HA case-patients, 44 were from HACO case-patients
(including 1 isolate of a unique PFGE type), and 27 were
from CA case-patients (including 1 isolate that could not
be typed) (Table 2). Of the HA isolates, 8 (28%) were
USA300. Of the HACO isolates, 6 (14%) were USA300, 1
(2%) was USA400, and 1 (2%) was USA1000. Thus,
18%–28% of isolates in patients with HRFs (HA and
HACO) had PFGE patterns typical of community strains.
Of the 27 isolates from CA case-patients, 5 (19%) were
USA100 and 2 (7%) were USA500; thus, 7 (26%) of iso-
lates among CA case-patients were strains typically con-
sidered to be of healthcare origin.
Conclusions
MRSA strains such as USA300, which were initially a
cause of MRSA infections in the community, have migrat-
ed into healthcare settings. The results from this multisite
project are consistent with observations from individual
facilities, where USA300 isolates caused illness in patients
whose infection was healthcare associated (11,12).
DISPATCHES
1992 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 12, No. 12, December 2006Although age and frequency of endocarditis still differed
between case-patients with HRFs (HA and HACO) and
those without HRFs (CA), PFGE testing indicated that
18%–28% of patients with HRFs were infected with a
“community-associated” strain of MRSA, primarily
USA300. Furthermore, 26% of patients without HRFs had
a “healthcare-associated” strain, typically USA100. Thus,
the distinction between healthcare- and community-associ-
ated MRSA is rapidly blurring.
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